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Synopsis
Aspergillus fumigatus is the causative agent of IA (invasive aspergillosis) in immunocompromised patients. It pos-
sesses a cell wall composed of chitin, glucan and galactomannan, polymeric carbohydrates synthesized by processive
glycosyltransferases from intracellular sugar nucleotide donors. Here we demonstrate that A. fumigatus possesses
an active AfAGM1 (A. fumigatus N-acetylphosphoglucosamine mutase), a key enzyme in the biosynthesis of UDP
(uridine diphosphate)–GlcNAc (N-acetylglucosamine), the nucleotide sugar donor for chitin synthesis. A conditional
agm1 mutant revealed the gene to be essential. Reduced expression of agm1 resulted in retarded cell growth and
altered cell wall ultrastructure and composition. The crystal structure of AfAGM1 revealed an amino acid change in
the active site compared with the human enzyme, which could be exploitable in the design of selective inhibitors.
AfAGM1 inhibitors were discovered by high-throughput screening, inhibiting the enzyme with IC50s in the low μM range.
Together, these data provide a platform for the future development of AfAGM1 inhibitors with antifungal activity.
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INTRODUCTION
Aspergillus fumigatus is a human fungal pathogen capable of
causing infections ranging from allergic to invasive disease [1],
and the major cause of IA (invasive aspergillosis) in immuno-
compromised patients [2]. In these patients, the crude mortality
is 30–95 % and remains about 50 % even when treatment is given
[3,4]. Antifungal drugs such as azoles, polyenes and candins are
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usually recommended for IA treatment [5]. However, new drugs
are urgently needed due to the inefficacy, side effects and resist-
ance that have emerged as important factors limiting successful
clinical outcome [6,7].
Since the fungal cell wall is essential for viability and absent
from the human cell, it has been recognized as an attractive target
for the development of new antifungal agents. The core of the A.
fumigatus cell wall is formed by a branched glucan–chitin com-
plex, embedded in an amorphous ‘cement’ composed of linear
c© 2013 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
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chains of α-glucan, galactomannan and polygalactosamine [8].
Chitin, accounting for approximately 10–20 % of the cell wall
[9], is synthesized by chitin synthases that use UDP (uridine
diphosphate)–GlcNAc as the sugar donor. In addition, UDP–
GlcNAc is also utilized in the biosynthesis of cell wall mannopro-
teins and GPI (glycosylphosphatidylinositol)-anchored proteins
[10,11].
In eukaryotes, UDP–GlcNAc (N-acetylglucosamine) is
synthesized from Fru-6P (fructose 6-phosphate) by four suc-
cessive reactions: (i) the conversion of Fru-6P into GlcN-6P
(glucosamine 6-phosphate) by GFA1 (glutamine: Fru-6P amido-
transferase); [12] the acetylation of GlcN-6P into GlcNAc-6P
by GNA1 (GlcN-6P acetyltransferase); (iii) the interconver-
sion of GlcNAc-6P into GlcNAc-1P (N-acetylglucosamine-1-
phosphate) by AGM1 (N-acetylphosphoglucosamine mutase);
and (iv) the uridylation of GlcNAc-1P into UDP–GlcNAc by
UAP1 (UDP–GlcNAc pyrophosphorylase) [13]. The third en-
zyme, AGM1, is a member of the α-D-phosphohexomutase su-
perfamily, that catalyses intramolecular phosphoryl transfer on a
range of phosphosugar substrates [14]. AGM1 has been isolated
and characterized from Saccharomyces cerevisiae, Candida al-
bicans and Homo sapiens [15–18]. It has been reported that the
AGM1 enzyme requires a divalent metal ion such as Mg2 + as
a co-factor, but the reaction is inhibited by Zn2 + ions [19,20].
The sequence motif Ser/Thr–X–Ser–His–Asn–Pro is highly con-
served and priming phosphorylation of the serine at the third
position is required for full activity [15,21–23]. To date, only
the crystal structure of CaAGM1 (Candida albicans AGM1) has
been reported, revealing four domains arranged in a ‘heart-shape’
[14]. The overall structure is similar to those of phosphohex-
omutases such as phosphoglucomutase/phosphomannomutase
from Pseudomonas aeruginosa [24]. The agm1 gene is essen-
tial for cell viability in S. cerevisiae [17]. Mice lacking the agm1
homologue (pgm3) die prior to implantation, whereas hetero-
zygotes have intrinsic haematopoietic and reproductive defects
[25]. Although AGM1 has been proposed as a potential drug
target, the issue of selectivity has not been explored and to
date no drug-like inhibitor has been described for this class of
enzyme.
Here, we show that A. fumigatus possesses a functional AGM1
enzyme that is essential for cell viability and cell wall synthesis. A
crystal structure of the enzyme revealed the possible exploitable
differences in the active site compared with the human enzyme.
Using a high-throughput screening approach, we identified the
first low micromolar inhibitors for this enzyme.
MATERIALS AND METHODS
Reagents, strains and growth conditions
Glc-1P (glucose-1-phosphate), Glc-6P (glucose-6-phosphate),
G6PDH (glucose-6-phosphate dehydrogenase) from Leucon-
ostoc mesenteroides , GlcNAc-6P, NAD+ and anthraquinone
compounds were purchased from Sigma-Aldrich, UAP1 from A.
fumigatus was a gift from Dr Ramo´n Hurtado-Guerrero, Univer-
sity of Dundee, UDP-Glc pyrophosphorylase from Trypanosoma
brucei was a gift from Dr Karina Marin˜o, University of Dundee
[26].
A. fumigatus strain KU80pyrG− derived from
KU80pyrG+ [27], a kind gift from Jean-Paul Latge´, In-
stitut Pasteur, France, was propagated at 37 ◦C on YGA (0.5 %
yeast extract, 2 % glucose, 1.5 % Bacto-agar) with addition of
5 mM uridine and uracil. The Aspergillus nidulans alcA promoter
(PalcA) was induced by growing on the MM (minimal medium)
[28] with 0.1 M glycerol, 0.1 M threonine or 0.1 M ethanol as car-
bon sources. YEPD (2 % (w/v) yeast extract, 2 % (w/v) glucose
and 0.1 % (w/v) peptone) medium and CM (complete medium)
[29] were utilized to repress the PalcA completely and partially,
respectively. Strains were grown in liquid medium at 37 ◦C,
with shaking at 200 rev./min. At the specified culture time point,
mycelia were harvested, washed with distilled water, frozen in
liquid N2 and then ground using a mortar and pestle. The powder
was stored at − 70 ◦C for DNA, RNA and protein extraction.
Conidia were prepared by growing A. fumigatus strains on
solid medium with or without uridine and uracil for 48 h at 37 ◦C.
The spores were collected, washed twice then resuspended in
0.1 % (v/v) Tween 20 in saline solution, and the concentration of
spores was confirmed by haemocytometer counting and viable
counting.
Cloning of agm1
The coding sequence of Af AGM1 (A. fumigatus N-
acetylphosphoglucosamine mutase) (accession: XP_750370)
was amplified by PCR from an A. fumigatus cDNA library (kindly
provided by Jean-Paul Latge´, Institut Pasteur, France) using the
forward primer P1 (5′- GCGAATTCATGGCGTCTCCAGCCG-
TTCGC-3′) and the reverse primer P2 (5′- CTGCGGCCGC-
TTAAGAAGCCTGCAAGATTTCTTTGACGGTG-3′), exploit-
ing the EcoRI and NotI restriction sites, for cloning into pGEX-
6P1 (GE Healthcare) following a modification that removed the
BamHI site from the original pGEX-6P1 vector such that the
EcoRI site immediately followed the PreScission Protease cod-
ing sequence. The cloned protein sequence had a deletion of the
amino acid residues VSSYGTFDGGMKGEFAD, correspond-
ing to residues 85–101 of the reference XP_750370 sequence,
but the protein sequence alignment with Aspergillus clavatus
(XP_001269528) and Neosartorya fischeri (XP_001265046) N-
acetylglucosamine-phosphate mutase sequences suggested that
this deletion is most likely because of alternative splicing. All
plasmids were verified by sequencing using the University of
Dundee sequencing service.
Construction of the conditional inactivation mutant
Plasmid pAL3 containing the PalcA and the Neurospora crassa
pyr-4 gene as a fungal selectable marker [30] was employed
to construct a suitable vector allowing the replacement of the
native promoter of the A. fumigatus agm1 gene with the PalcA.
To this end, an 898 bp fragment from − 32 to + 866 of agm1
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was amplified with primers P3 (5′-GGGGTACCACACGACT-
TTCGCCAGGTC-3′, containing a KpnI site) and P4 (5′-G-
CTCTAGATCCTTGCTCAGTAGGCTCAC-3′, containing an
XbaI site). The PCR-amplified fragment was cloned into the
expression vector pAL3 to yield pALAGM1N and confirmed
by sequencing. The pALAGM1N was used to transform strain
KU80pyrG− by PEG-mediated fusion of protoplasts [31] and
positive transformants were selected by uridine/uracil autotrophy.
Genotyping of the transformants was performed by PCR and
Southern blot analysis. For PCR analysis, three pairs of primers
were employed. Primers P5 (5′- ATGGCGTCTCCAGCCGTT-
3′) and P6 (5′- TTAAGAAGCCTGCAAGATTTC-3′) were used
to amplify the agm1 gene (2 kb). Primers P7 (5′-AAACGCAA-
ATCACAACAGCCAAC-3′) and P8 (5′-CTATGCCAGACG-
CTCCCGG-3′) were used to amplify the pyr-4 gene (1.2 kb).
Primers P9 (5′- TCGGGATAGTTCCGACCTAGGA-3′) and P10
(5′- TGATGCCAATACCCATCCGAG-3′) were used to amplify
the fragment from the PalcA to the downstream flanking region
of the agm1 gene (2.8 kb). For Southern blotting, genomic DNA
was digested with PstI, separated by electrophoresis, and trans-
ferred to a nylon membrane (Zeta-probe+ , Bio-Rad). The 898-bp
fragment of agm1 and a 1.2 kb HindIII fragment of the N. crassa
pyr-4 gene from pAL3 were used as probes. Labelling and visual-
ization were performed using the DIG DNA labelling and detec-
tion kit (Roche Applied Science) according to the manufacturer’s
instructions.
Quantitative PCR
Total RNA from the spores cultured in liquid MM was extracted
using Trizol reagent (Invitrogen). cDNA synthesis was performed
with 5 μg RNA using the SuperScript-First-Strand Synthesis Sys-
tem (Fermentas). Primers P11 (5′- TGTTGGAAGCTGAATGG-
GAAGC -3′) and P12 (5′-CGATCTCCTTAAC CAATTCGTCG
-3′) were used to amplify a 96-bp fragment of agm1, and
primers P13 (5′-CCACCTTGCAAAACATTGTT-3′) and P14
(5′-TACTCTGCATTTCGCGCATG-3′) were used for an 80-bp
fragment of tbp gene (encoding TATA-box-binding protein).
To exclude contamination of cDNA preparations with genomic
DNA, primers were designed to amplify regions containing one
intron in the gene [32,33]. Each PCR reaction mixture (20 μl)
contained 8 μl sample cDNA, 0.4 μl ROX Reference Dye and
10 μl SYBR Premix Ex TaqTM from the SYBR Premix Ex TaqTM
Kit (TAKARA), 0.8 μl ddH2O and 0.2 μM of each pair of
primers. Thermal cycling conditions were 50 ◦C for 2 min and
95 ◦C for 1 min, followed by 40 cycles of 95 ◦C for 5 s, 60 ◦C
for 60 s. Real-time PCR data were acquired using Sequence De-
tection software. The standard curve method [34] was used to
analyse the real-time PCR data. Samples isolated from different
strains and at different times were tested in triplicate.
Electron microscopy and chemical analysis of the
cell wall
To monitor the development of the cell wall structures, the
conidia and mycelia grown in solid and liquid MM were fixed
and examined with an H-600 electron microscope as described
by Li et al. [35]. For the chemical analysis of the cell wall,
conidia were inoculated into 100 ml MM or MMG liquid
medium at a concentration of 106 conidia ml− 1 and incubated at
37 ◦C with centrifugation (200 rev/min) for 36 h. The mycelium
was harvested, washed with deionized water and frozen at
− 80 ◦C. The cell wall components were isolated and assayed
as described previously [36]. Three independent samples of
lyophilized mycelial pad were used for cell wall analysis, and
the experiment was repeated twice.
AfAGM1 production and purification
LB medium (1 l) containing 0.1 mg ml− 1 ampicillin was inocu-
lated with 10 ml of an overnight culture of BL21 (DE3) pLysS
cells harbouring the plasmid, and grown at 37 ◦C to A600 = 0.8; at
this absorbance , the temperature was reduced to 20 ◦C and protein
expression was induced by the addition of 250 μM IPTG (isopro-
pyl β-D-thiogalactoside) and the incubation time was prolonged
for a further 18 h. The cells were harvested by centrifugation at
3500 g at 4 ◦C for 30 min, resuspended in Tris buffer (25 mM Tris,
150 mM NaCl, pH 7.5) containing lysozyme, DNAse (Sigma)
and a tablet of protease inhibitor cocktail (Roche). Cells were
lysed using a French press at 1000 psi. The insoluble fraction
was removed by centrifugation at 40 000 g for 30 min and the
supernatant was incubated with Glutathione Sepharose 4B beads
(GE Healthcare) previously equilibrated with the same buffer for
2 h. The beads were collected by centrifugation at 1000 g for
3 min and washed using the same buffer. The beads were then
incubated with PreScission protease in the same buffer at 4 ◦C on
a rotating platform overnight. The cleaved protein was filtered
from the beads, concentrated and confirmed by SDS–PAGE. In
the last stage of purification, the protein was passed through a Su-
perdex75 gel filtration column (2.6 × 60 cm) (Amersham Bios-
ciences), previously equilibrated with 25 mM Tris buffer con-
taining 150 mM NaCl, pH 7.5. Concentrated protein (5 ml) was
loaded onto the column and eluted using the same buffer at 1.0 ml
min− 1 flow rate. Approximately 5 ml fractions were collected
and fractions containing the protein were pooled and concentrated
using a 10-kDa cut-off Vivaspin concentrator (GE Healthcare).
Liquid chromatography-Tandem MS
Reduction and alkylation was performed on pure Af AGM1 pro-
tein prior to digestion by trypsin. The resulting peptides were
dried down and reconstituted in 0.1 % (v/v) formic acid. Peptides
separated on a nano-C18 reverse phase column using a Dionex
3000 ultimate n-HPLC coupled to an LTQ-Orbitrap Velos mass
spectrometer (Thermo Fisher). The mass spectrometer operated
on a data-dependent CID mode, allowing automatic switching
between MS, MS/MS and MS3 or MSA. The five most abundant
ions from every full-scan over the range 340–1800 m/z at 60000
resolution in the Orbitrap analyzer were fragmented by MS/MS in
parallel in the linear ion trap LTQ (MS/MS). Data were processed
in Thermo Proteome Discoverer version 1.3 platform (Thermo
Fisher Scientific Inc.), mass data were searched by MASCOT
against ‘Uniprot_Swall _20120715’ protein database version
2.3, number of sequences 41660230, number of sequences
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after taxonomy: 207946; taxonomy specified: Aspergillus,
with a Precursor Mass tolerance of 10 ppm and fragment mass
tolerance of 0.6 kDa. Dioxidation (M), oxidation (M), phospho
(STY) were allowed as variable modifications and carbamido-
methyl (C) modification was fixed. The analysis layout included
a phosphoRS node to calculate the probability of phosphorylation
site mapping. The site mapping spectrum was manually inspected
and validated.
Protein crystallography
20 mg ml− 1 of pure Af AGM1 protein in 25 mM Tris buffer,
150 mM NaCl with pH 7.5 was used to screen for crystals at
20 ◦C using the sitting-drop vapour diffusion method. Each drop
contained 0.6 μl of the protein solution with an equal volume of
the mother liquor. To obtain the Af AGM1–Mg2 + complex, the
protein was incubated at 4 ◦C with 5 mM MgCl2 for 4 h before
setting up crystal trays. The complex crystallized after 2–3 days in
the space group P212121 (Table 3) from a mother liquor contain-
ing 0.1 M ammonium sulfate, 0.1 M sodium acetate trihydrate,
pH 4.6. X-ray data from the Af AGM1 crystal were collected at
the BM14 beam line of the European Synchrotron Radiation Fa-
cility (ESRF, Grenoble, France). Crystals were cryo-protected
with 15 % (v/v) glycerol in mother liquor and frozen in a nitro-
gen gas stream at 100 K. Data were processed with HKL2000
[37]. The structure of Af AGM1 was solved by molecular replace-
ment using MOLREP [38] with the CaAGM1 structure (PDBID
2DKA) [14] as the search model. Refinement was performed with
REFMAC5 [39] and model building with COOT [40]. Pictures
were generated using Pymol [41].
Enzyme kinetics
Four methods were used to measure Af AGM1 activity. The first
was a coupled assay with G6PDH as described by Liu et al. [42].
Briefly, the assay was carried out in a 100 μl reaction volume con-
taining 50 mM MOPS pH 7.4, 1.5 mM MgSO4, 1 mM DTT (di-
thiothreitol), a range of concentrations of Glc-1P, 1 mM NAD+
and 0.01 units of G6PDH. The reaction was started by the addi-
tion of 10 nM Af AGM1 and incubated for 60 min at 20 ◦C. The
amount of NADH produced was measured using the micro plate
fluorescence reader (FL×800).
A second assay involved UAP1 and pyrophosphatase as coup-
ling enzymes, as described by Mok and Edwards [43]. The reac-
tion mixture (100 μl) contained 50 mM MOPS pH 7.4, 1.5 mM
MgSO4, 250 μM UTP, varying concentrations of GlcNAc-
6P (2.5–300 μM), 100 nM Af AGM1, 0.5 μM Af UAP1 and
0.04 units pyrophosphatase to convert the Af UAP1 reaction
product PPi to inorganic phosphate. The reaction was incub-
ated at 20 ◦C for 30 min and terminated by the addition of 100 μl
Biomol green (0.03 % (w/v) malachite green, 0.2 % (w/v) am-
monium molybdate and 0.5 % (v/v) Triton X-100 in 0.7 N HCl)
and left for a further 20 min at 20 ◦C for colour development.
Absorbance at 620 nm was read using a spectrophotometer.
A third assay involved coupling with UDP-glucose pyrophos-
phorylase using Glc-6P as the substrate, using the Biomol green
assay as described [26].
A fourth assay was used to monitor product formation directly.
The reaction mixture (100 μl) contained 50 mM MOPS buffer
pH 7.4, 1.5 mM MgSO4, 1 mM Glc-1P and 20 nM Af AGM1.
The reaction was incubated at 20 ◦C for 30 min and terminated
by adding 100 μl of 0.2 M NaOH. The samples were analysed
by High Performance Anion Exchange Chromatography coupled
to a Pulse Amperometric Detector (HPAEC-PAD, Dionex) using
a CarboPac PA1 column and conditions adapted from Zhou et
al. [44]. Briefly, a linear gradient from 150 mM sodium acet-
ate (Merck), 0.1 M NaOH to 400 mM sodium acetate, 0.1 M
NaOH was applied over 25 min, before lowering the concentra-
tion of sodium acetate back to the initial conditions over 5 min.
The column was then re-equilibrated at 150 mM sodium acet-
ate, 0.1 M NaOH for 5 min. The flow rate was kept constant at
0.25 ml min− 1.
Inhibitor screening
The Prestwick library (Prestwick chemical, France, 1120 com-
pounds) and the LOPAC library (Sigma, 1280 compounds) were
screened at 100 μM using the G6PDH coupled Af AGM1 assay.
Compounds with percentage inhibition of 40 % were investig-
ated as possible hits. The compounds were purchased and false
positives eliminated by testing inhibition of the coupling enzyme.
IC50s of the most potent compounds against Af AGM1 were es-
timated using the direct assay method described above.
In vivo AfAGM1 activity assay and MIC (minimum
inhibitory concentration) assay
For in vivo protein extraction, the ground frozen powder was dis-
solved in 50 mM Tris–HCl pH 7.5 and placed on ice for 30 min.
Intracellular proteins were collected by centrifugation. In order
to eliminate PPi derived from the intracellular extract, a 10 kDa
cut-off concentrator was used with each sample. Protein con-
centration was determined using the Folin–phenol method [45].
The Af AGM1 activity was determined as described by Mok and
Edwards [43].
Three compounds were tested against A. fumigatus accord-
ing to the Clinical and Laboratory Standards Institute (formerly
NC-CLS) M38-A microdilution methodology. Briefly, conidial
suspensions of 105 ml− 1 were dispensed (100 μl) into a mi-
crotiter plate containing serial two-fold dilutions of compounds.
After incubating at 37 ◦C for 48 h, growth was visually inspec-
ted. The MIC endpoint was defined as the lowest concentration
producing complete inhibition of growth.
RESULTS AND DISCUSSION
A. fumigatus possesses a functional AGM1
A BLASTp search of the A. fumigatus genome revealed the ex-
istence of a putative agm1 gene. The coding sequence of the
gene was amplified by PCR from an A. fumigatus cDNA lib-
rary, cloned into pGEX-6P-1 and overexpressed as a GST-fusion
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Figure 1 Steady-state kinetics of AfAGM1
Initial steady-state velocities are shown for AfAGM1 using different concentrations of (A) GlcNAc-6P, with AfUAP1 as
coupling enzyme; (B) Glc-1P, with G6PDH as the coupling enzyme; details are described in the Materials and Methods
section. The results are the mean +− S.D. for three determinations.
Table 1 Kinetic parameters of AfAGM1
The coupled assay with G6PDH was used to measure AfAGM1 activity with Glc-1P as the substrate in the
presence or absence of Glc-1,6-P2. The colorimetric assay involving purified AfUAP1 or Trypanosoma brucei
UDP-glucose pyrophosphorylase as coupling enzymes was used to measure AfAGM1 activity with GlcNAc-6P
or Glc-6P as the substrate. The results are the mean +− S.D. for three determinations.
Substrate Km (μM) Vmax (μM s−1) kcat (s−1) kcat/Km (μM−1 s−1)
Glc-1P 1200 +− 100 0.38 +− 0.01 37.6 0.0313
Glc-1P + Glc-1, 6-P2 400 +− 30 0.41 +− 0.01 41.0 0.1025
GlcNAc-6P 25 +− 8 0.021 +− 0.002 0.21 0.0084
Glc-6P 300 +− 48 0.018 +− 0.001 0.18 0.0006
protein in Escherichia coli. Purification using glutathione beads
followed by GST cleavage and size exclusion chromatography
yielded 4 mg of pure Af AGM1 per litre of bacterial culture. A
coupled assay with A. fumigatus UAP1 as the coupling enzyme
was used to investigate the activity of Af AGM1 towards the
predicted physiological substrate, GlcNAc-6P, yielding a Km of
25 +− 8 μM (Figure 1A, Table 1). This is comparable with the Km
of 46 μM obtained for HsAGM1 for the same substrate [15].
Enzymes of the α-D-phosphohexomutase superfamily have
been reported to be promiscuous in terms of their phosphohexose
substrate specificity [22]. Indeed, Af AGM1 is active on Glc-1P
as demonstrated with a different coupled assay, with G6PDH
as a coupling enzyme, revealing a Km of 1200 +− 100 μM (Fig-
ure 1B, Table 1). This is different from the 12 +− 1 μM Km
obtained for PaPMM/PGM [46], suggesting Af AGM1 is more
selective for GlcNAc phosphosugars. The presence of glucose-
1,6-bisphosphate, an activator normally needed for this super-
family, did not enhance the activity implying that the enzyme
may have been purified as the active, phosphorylated form [23].
Af AGM1 is also capable of converting Glc-6P into Glc-1P with a
Km of 300 μM, investigated using T. brucei UDP-glucose pyro-
phosphorylase as the coupling enzyme (Table 1). However, the
kcat/Km values for GlcNAc-6P, Glc-1P and Glc-6P were 0.0084,
0.0313 and 0.0006 μM− 1s− 1, respectively, demonstrating that
Af AGM1 has higher catalytic efficiency for Glc-1P than for
GlcNAc-6P and Glc-6P (Table 1).
AfAGM1 is essential for A. fumigatus survival
In fungi, AGM1 catalyzes an important step in the synthesis of
UDP–GlcNAc, an important precursor for the synthesis of chitin,
a key component of the fungal cell wall. Deletion of AGM1 in S.
cerevisiae has been shown to be lethal [13,17]. We first attemp-
ted to construct a deletion mutant in A. fumigatus by replacing
the agm1 gene with a pyrG gene. A total of 108 transformants
were screened, none of them was positive. Therefore a condi-
tional inactivation mutant was constructed by replacing the nat-
ive promoter of the agm1 gene with PalcA, a tightly regulated
promoter that can be induced by ethanol, glycerol or threon-
ine, and repressed completely on the YEPD medium [30,47]. To
this end, a plasmid (pALAGM1N) that contains the pyr-4 gene
and PalcA fused to a 3′-end truncated version of the agm1 gene
was employed in transformation of A. fumigatus KU80pyrG−
to generate a strain carrying the PalcA-agm1 fusion gene by ho-
mologous recombination. One mutant named AGM1 was con-
firmed to be correct by PCR and Southern blot analysis. PCR
analysis revealed that a 1217-bp fragment of pyr-4 and a 2764-
bp fragment of PalcA-agm1 could be amplified from the mutant,
while no such fragment was amplified from the wild-type strain
(Figure 2A). When an 898-bp fragment of the agm1 gene was
used as probe, the expected 4.2 kb fragment was found in the
wild-type, whereas the expected 3.3 and 7 kb fragments were de-
tected in the AGM1 strain (Figure 2B). When the 1.2 kb fragment
of the pyr-4 gene was used as a probe, no fragment was found in
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Figure 2 Generation of a conditional agm1 mutant
(A) PCR confirmation of the agm1 mutant using primer pairs P5 and P6, P7 and P8, P9 and P10 to amplify the agm1 gene,
the pyr-4 gene and the fragment of PalcA- downstream of agm1, respectively. (B) Southern blot using an 898-bp fragment
of the agm1 gene as probe (probe 1). (C) Southern blot using a 1.2 kb HindIII internal fragment of the N. crassa pyr-4 gene
as probe (probe 2). (D) Growth of A. fumigatus strains on solid MM supplemented with 0.1 M glycerol, ethanol, threonine
or 1, 2, 3 % glucose, YEPD or CM, using serial dilutions from 105–102 conidia.
the wild-type, whereas the expected 7 kb fragment was detected
in the AGM1 strain (Figure 2C). These results demonstrated that
the promoter of the agm1 gene was replaced with the PalcA in the
AGM1 strain.
The AGM1 strain grew normally on the solid MM contain-
ing 0.1 M glycerol (MMG), 0.1 M ethanol or 0.1 M threonine at
37 ◦C for 36 h, whereas its growth was significantly inhibited on
MM medium containing 1–3 % glucose and completely retarded
on YEPD or CM (Figure 2D), demonstrating that Af AGM1 is
essential for A. fumigatus viability. Total suppression of agm1
expression led to cell death. This suggests that no other members
of the phosphohexomutase superfamily can substitute AGM1 in
A. fumigatus, although the enzyme itself possesses both phos-
phoglucomutase and phosphoacetylglucosamine mutase activity
(Figure 1 and Table 1).
In order to investigate the function of Af AGM1, MM contain-
ing 1 % glucose (MM) was chosen for subsequent experiments.
Under this condition, total RNAs were prepared from mycelia and
the transcription levels of agm1 in mutant and wild-type were ex-
amined by real-time quantitative PCR. Using relative standard
curve quantitation, the transcription level of the agm1 gene in
the AGM1 strain was reduced to 32 % of the wild-type transcript
level. Intracellular proteins were extracted from mycelium cells
and investigated for Af AGM1 activity using the Af UAP1 coupled
assay revealing a 50 % reduction in AGM1 activity.
AfAGM1 is important for cell wall synthesis and
ultrastructure
Examination of the ultrastructure of the spore and hyphal cell
wall revealed the spore of the AGM1 strain is similar to that of
wild-type upon induction of agm1 expression (using MM sup-
plemented with 0.1 M glycerol, MMG) (Figure 3A). Using gene
repression (with MM), the spore and hyphae of strain AGM1 had
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Figure 3 TEM spore and mycelia morphology for wild-type and
agm1 mutant strain
Wild-type and strain AGM1 grown under (A) conditions of agm1 induc-
tion and (B) conditions of agm1 repression. Conidia and mycelia were
collected after growing in solid or liquid MM and MMG media at 37 ◦C for
36 h, fixed as described under the Materials and Methods section. The
sections were examined with an H-600 electron microscope (Hitachi).
Bar: 0.2 μm for conidia; 0.5 μm for mycelia.
a thinner cell wall, unable to retain surface melanin (Figure 3B).
Furthermore, the cell wall contents were analysed. With agm1
induction, the cell wall components of the AGM1 strain were
similar to those in wild-type. With agm1 suppression, the con-
tent of α-glucan and β-glucan was increased by 25 and 33 %,
respectively; the amounts of glycoprotein and chitin in strain
AGM1 were decreased by 16 and 19 %, respectively; GlcNAc
released from cell wall proteins was decreased by 34 % and man-
nose was increased by 14 % (Table 2). These results suggest that
the suppressed expression of agm1 induces a decreased content
of chitin and GlcNAc in the A. fumigatus cell wall, presumably
as a direct consequence of the decreased pools of the UDP–
GlcNAc precursor. Although α/β-glucan contents were found to
be increased (perhaps by the activation of the cell wall integrity
signalling pathway [48,49]), this did not effectively compensate
for the reduction of chitin, indicating that Af AGM1 is essential
for cell wall synthesis in A. fumigatus.
AfAGM1 possesses structurally exploitable
differences compared with the human enzyme
The agm1 gene disruption provides genetic validation of
Af AGM1 as a potential antifungal target in A. fumigatus, jus-
Table 3 Details of diffraction data collection and structure
refinement
Values between brackets are for the highest resolution shell. All meas-
ured data were included in structure refinement.
Measurement AfAGM1+Mg2+
Resolution 25.00 (2.35)
Space group P212121
Unit cell
a (A˚) 74.7
b (A˚) 86.6
c (A˚) 185.4
No. of reflections 183592
No. of unique reflections 48393
I/σ (I) 34.7 (1.8)
Completeness (%) 99.87
Redundancy 3.5 (3.9)
Rmerge (%) 5.7 (66.6)
RMSD from ideal geometry
Bond distance (A˚) 0.010
Bond angle (◦) 1.39
Rwork (%) 21.8
Rfree (%) 27.7
No. of residues 987
No. of water mol. 38
B factors (A˚2)
Overall 18.9
Protein 17.8
Ligand 53.3
tifying efforts towards the discovery of inhibitors of this enzyme.
Although the structure of human AGM1 has not been reported,
this enzyme is 49.3 % identical to Af AGM1 at the amino acid
sequence level. Given that mice lacking the agm1 orthologue die
prior to implantation [25] it is essential to discover inhibitors that
selectively inhibit the fungal enzyme over the human orthologue.
To investigate possible differences in the active site compared
with the human enzyme, the crystal structure of Af AGM1 in
complex with magnesium was determined to 2.35 ˚A resolution
(Table 3), with two protein molecules in the asymmetric unit. The
molecules interact via a 553 ˚A2 contact surface area, suggest-
ing weak crystallographic (rather than physiologically relevant)
contacts, in agreement with the gel filtration trace that showed a
Table 2 Chemical analysis of the cell wall
Three aliquots of 10 mg lyophilized mycelia were used as independent samples for cell wall analysis, and the experiment was repeated twice. The
values shown are microgram of cell wall component per 10 mg dry mycelia ( +− S.D.).
Alkali soluble Alkali insoluble
Mannoprotein Chitin (μg) β-glucan (μg)
Culture condition Strain Protein (μg) GlcNAc (μg) Gal (μg) Man (μg) α-glucan (μg)
Induction (MMG) WT 36 +− 2 0.61 +− 0.02 5.2 +− 0.2 3.0 +− 0.2 328 +− 24 212 +− 3 1137 +− 57
AGM1 39 +− 2 0.64 +− 0.04 5.3 +− 0.3 2.9 +− 0.3 322 +− 22 230 +− 6 1360 +− 7
Repression (MM) WT 51 +− 3 0.61 +− 0.02 8.1 +− 0.3 4.9 +− 0.2 587 +− 45 194 +− 2 1172 +− 64
AGM1 43 +− 1 0.40 +− 0.02 7.7 +− 0.6 4.2 +− 0.2 735 +− 18 157 +− 2 1554 +− 4
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Figure 4 Crystal structure of AfAGM1 in complex with magnesium
(A) A structural overview of AfAGM1. Domain I, II, III and IV are coloured in cyan, yellow, purple and orange, respectively.
Secondary-structure elements of each domain are coloured red (helices) and blue (strands). The magnesium ion is shown
as sphere. pSer69 is show as a sticks model. (B) Close-up view of the AfAGM1 active site, showing the magnesium ion
(sphere), coordinating residues and pSer69 (sticks with grey carbon atoms). A model of GlcNAc-6P obtained by superpos-
ition with the CaAGM1–GlcNAc-6P complex (PDBID: 2DKC [14]) is shown as sticks with green carbon atoms. A molecular
surface is shown, coloured by sequence conservation with HsAGM1 (purple: identical side chains, grey: non-identical side
chains). (C) Annotated MS/MS spectrum of an AfAGM1 tryptic peptide covering the Ser69 phosphorylation site. On the top
of the panel an extensive coverage b- and y-type ions of the peptide fragment ions shown made the site of phosphoryla-
tion localization to be precisely determined on Ser69. This manual assignment was reinforced by the bioinformatics tool
‘phosphoRS’ a phosphorylation-site localization probabilities software calculator ‘phosphoRS’ version 1.3.0.339 (Thermo
Fisher Scientific Inc.) results shown on top over the peptide sequence.
monomer in solution. The overall structure of this enzyme is sim-
ilar to that of CaAGM1 [14] (51.6 % sequence identity, RMSD
(root mean square deviation) of 1.2 ˚A on 496 Cα atoms) and the
PaPMM/PGM [24] (19.6 % sequence identity and RMSD of 2.3
˚A on 343 Cα atoms). Like other members of this superfamily,
Af AGM1 consists of four domains (Figure 4A) forming a heart
shape. Domain 1 (residues 1–187) bears the predicted active ser-
ine loop, domain 2 (residues 188–305) bears the metal-binding
loop, domain 3 (residues 306–442) bears the sugar-binding loop
and domain 4 (residues 443–542) bears the phosphate-binding
loop. Although the Af AGM1 structure was determined in ab-
sence of any substrates or products, all amino acids important for
substrate binding and catalysis, as gleaned from the CaAGM1
structure, are conserved, in agreement with the observed cata-
lytic activity of Af AGM1 (Figure 4B). Strikingly, the electron
density revealed a phosphorylated active site S69 (Figure 4A),
which was confirmed separately by mass-spectrometric phos-
phosite mapping (Figure 4C), explaining why the enzyme is act-
ive in absence of glucose-1,6-bisphosphate (Table 1), an activator
normally required to load the active site of this class of enzyme
with a phosphate [23,46,50]. It is probably that Af AGM1 be-
came phosphorylated during expression in the E. coli host. It is
known that enzymes of the wider family of phosphohexomutases
are magnesium-dependent. In Af AGM1, the magnesium ion is
pentagonally coordinated in a square-pyramidal arrangement by
pSer69, Asp284, Asp286 and Asp288 (Figure 4B). This type of
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Figure 5 Inhibitors of AfAGM1
(A) Structures of the AfAGM1 inhibitors identified by high-throughput screening. 1: 1,5-diamino-4,8-dihydroxyanthraquinone,
2: 2-chloro-1,5-diamino-4,8-dihydroxyanthraquinone (Disperse Blue 56), 3: 6-hydroxy-DL-DOPA, 4: (tri-sodium
4-[(2z)-2-[4-formyl-6-metyl-5-oxo-3-(phosphonatooxymetyl)-pyridin-2-ylidene] hydrazinyl] benzoate). (B) Lineweaver–Burk plot
of inhibition of AfAGM1 by compound 1, giving a Ki of 300 +− 13 μM. (C) HPAEC-PAD chromatogram for the direct assay of
Glc-1P and Glc-6P showing inhibition of AfAGM1 activity; 1. The positive control (without inhibitor); 2. Reaction containing
100 μM compound 3; and 3. Reaction containing 100 μM compound 4. (D) IC50 curves of compounds 3 and 4 inhibition
of AfAGM1 using the HPAEC-PAD assay and 1 mM Glc-1P substrate.
coordination has also been described for the structure of
CaAGM1 complexed with either GlcNAc-1P or GlcNAc-6P and
Zn acting as an inhibitor [14].
Although the catalytic machinery is fully conserved, careful
analysis of sequence conservation in the active site area revealed
that the human and fungal enzymes possess differences near the
substrate-binding site (Figure 4B). For example, within the loop
carrying the catalytic serine, Af AGM1 Ala73 is equivalent to
Glu68 in the human enzyme. The sugar phosphate-binding loop
harbours Ala506 and Ala512 in Af AGM1, equivalent to Pro497 and
Val503 in the human enzyme, respectively. Within the active site
itself, located close to the phosphoGlcNAc binding site, Val425
occupies a position in Af AGM1 that is equivalent to the smaller
Ala416 in the human enzyme (Figure 4B). Such differences can
be exploited in the design of inhibitors to selectively target the
fungal enzyme.
Screening-based discovery of micromolar AfAGM1
inhibitors
To identify potential inhibitors of Af AGM1, high-throughput
screening of the Prestwick (1120 compounds) and Sigma LOPAC
(1280 compounds) libraries was carried out at 100 μM com-
pound concentration. Screening was performed using the G6PDH
coupled assay. Compounds with percentage inhibition of 40 %
were considered to be hits, corresponding to 84 compounds
(3.5 %) of the total screened. These compounds were tested
against the coupling enzyme, resulting in a pool of 16 true pos-
itive hits. Where possible, structural representatives of different
scaffolds were purchased and retested on Af AGM1. A group
of anthraquinone-based compounds were found to be the most
potent Af AGM1 inhibitors identified from the Prestwick screen
with 1,5-diamino-4,8-dihydroxyanthraquinone (Figure 5A, com-
pound 1) having a Ki of 300 +− 13 μM by a non-competitive
mixed inhibition mechanism (Figure 5B). Interestingly, a sim-
ilar compound, the organic dye Disperse Blue 56 (2-chloro-1,5-
diamino-4,8-dihydroxyanthraquinone) (Figure 5A, compound 2)
was identified by virtual screening method as an inhibitor of
PaPMM/PGM with an IC50 of 5 μM [42]. The authors observed
that inhibition of this enzyme was due to aggregation of the com-
pound. However, no inhibition of PaPMM/PGM was observed
when the compound 1 was tested [42]. The selectivity of this com-
pound may be the result of the dissimilarity between Af AGM1
and PaPMM/PGM (sequence identity of only 19.6 %).
The other compounds, compound 3 (6-hydroxyl-DL-DOPA)
and compound 4 (tri-sodium 4-[(2z)-2-[4-formyl-6-metyl-5-oxo-
3-(phosphonatooxymetyl)-pyridin-2-ylidene] hydrazinyl] ben-
zoate) (Figure 5A) from the LOPAC screen were tested against
Af AGM1 by a direct assay method using HPAEC-PAD (Fig-
ure 5C) to avoid the observed slight inhibition of the coupling
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
c© 2013 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
697
W. Fang and others
enzyme and were found to inhibit Af AGM1 activity with IC50s
of 58 +− 4 μM and 7.1 +− 0.2 μM for the compounds 3 and 4, re-
spectively (Figure 5D). When compounds 1, 3 and 4 were tested
on A. fumigatus cultures, compounds 1 and 3 showed severe
precipitation during dilution for the MIC assay, whereas com-
pound 4 did not inhibit growth of either the wild-type or AGM1
mutant strains at concentrations up to 1.4 mM. Although these
compounds are not active against A. fumigatus, either because of
the solubility of the compounds, limited cell penetration or low
efficacy, they are the first low micromolar inhibitors identified
for the phosphohexomutase superfamily. Structural complexes
of these inhibitors with Af AGM1 and synthesis of derivatives to
address solubility, penetration and potency may lead to insights
into mode of action and generation of molecules reproducing the
genetic phenotype of the agm1 gene knockout.
In conclusion, by combination of genetic and structural ap-
proaches we have validated Af AGM1 as a potential antifungal
drug target. Together with the novel compounds identified here,
these results provide a platform for the development of AGM1
inhibitors that target fungal cell wall synthesis.
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